CONGRESS|#EHA2021|@MyMKaiser, Institute of Cancer Research highlighted myeloma molecular risk in the era of modern agents. Use of validated risk markers and quantitative molecular risk assessment is important to identify unmet needs of pts at diagnosis. #mmsm, #myeloma pic.twitter.com/Qt255PExS9
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021